Objective: We hypothesized that metachronous colorectal liver metastases (CLM) have different biology after failure of oxaliplatin (FOLFOX) compared to 5-fluorouracil (5-FU) or no chemotherapy for adjuvant treatment of colorectal cancer (CRC). Background: It is unclear whether patients treated with liver resection for metachronous CLM after adjuvant FOLFOX for CRC have worse outcomes than those who received 5-FU or no chemotherapy. Methods: We identified 341 patients who underwent hepatectomy for metachronous CLM (disease-free interval ≥12 months, 1993-2010). Massspectroscopy genotyping for somatic gene mutations in CLM was performed in a subset of 129 patients. Results: Adjuvant treatment for primary CRC was FOLFOX in 77 patients, 5-FU in 169 patients, and no chemotherapy in 95 patients. Node-positive primary was comparable between FOLFOX and 5-FU but lower in the nochemotherapy group (P < 0.0001). Median metastasis size was smaller in the FOLFOX group (2.5 cm) than in the 5-FU (3.0 cm) or no-chemotherapy (3.5 cm) groups, (P = 0.008) although prehepatectomy chemotherapy utilization, metastases number, and carcinoembryonic antigen levels were similar. Disease-free survival (DFS) and overall survival (OS) rates after hepatectomy were worse in patients treated with adjuvant FOLFOX [DFS at 3 years: 14% vs 38% (5-FU) vs 45% (no-chemo), OS at 3 years: 58% vs 70% (5-FU) vs 84% (no-chemo)]. On multivariate analysis, adjuvant FOLFOX was associated with worse DFS (P < 0.0001) and OS (P < 0.0001). Mutation analysis revealed ≥1 mutations in 57% of patients (27/47) after FOLFOX, 29% (12/41) after 5-FU, and 32% (13/41) after no chemotherapy (P = 0.011). Conclusions: Adjuvant FOLFOX for primary CRC is associated with a high rate of somatic mutations in liver metastases and inferior outcomes after hepatectomy for metachronous CLM. Western countries.
Western countries. 1 CRC resection with regional lymphadenectomy is the primary treatment of choice. The postoperative survival in these patients is significantly associated with tumor stage on the basis of the TNM classification system, which takes into consideration the depth of tumor penetration in the bowel wall and the extent of lymph node involvement. 2 Patients with positive lymph node metastases have a higher risk of local recurrence and metastasis, especially in the liver. Therefore, systemic therapy after resection of node-positive CRC has routinely been used to reduce the incidence of relapse. 3 Adjuvant chemotherapy with fluorouracil (5-FU) and leucovorin (FL) was established in the 1990s for stage III CRC to reduce recurrence and prolong survival. [4] [5] [6] Since 2004, oxaliplatin, in combination with 5-FU and FL (FOLFOX), has been used to treat stage II or stage III CRC after surgery. The MOSAIC randomized trial demonstrated that patients treated with this modern chemotherapy regimen have higher disease-free (DFS) and overall survival (OS) rates than those treated with 5-FU and FL alone. 7, 8 Despite adjuvant chemotherapy, approximately 20% of patients develop metachronous colorectal liver metastases (CLM) within 3 years. 9 Modern chemotherapy with FOLFOX has increased the recurrence-free survival rate after resection of the primary CRC; however, metastatic liver disease has not been completely eliminated. One fourth of patients with CLM are candidates for liver resection; curative hepatectomy, combined with perioperative systemic therapy, leads to 5-year OS rates as high as 58%. 10 However, in this era of modern chemotherapy, it is unclear whether patients treated with liver resection for metachronous CLM after adjuvant FOLFOX therapy for the primary CRC have poorer outcomes than those who received 5-FU or no chemotherapy.
In this retrospective study, we hypothesized that metachronous CLM have different biologic characteristics after failure of oxaliplatin compared with after 5-FU or no chemotherapy for adjuvant treatment of CRC. To investigate this hypothesis, we performed a survival analysis on 3 groups of patients who had undergone liver resection for metachronous CLM (diagnosis ≥ 1 year after resection of the CRC) and had received FOLFOX, 5-FU, or no chemotherapy for the primary tumor. The biologic characteristics of the CLM were evaluated on the basis of the presence of somatic gene mutations that are known to be associated with unfavorable outcome in metastatic CRC.
been treated with radiofrequency ablation (RFA) only or concomitant hepatectomy and RFA were not included in this analysis. All patients with disease-free interval between resection of the primary CRC and diagnosis of the CLM less than 12 months were considered to have synchronous CLM and were excluded. Patients who had undergone hepatectomy for metachronous CLM and had received adjuvant chemotherapy for the primary CRC other than 5-FU or FOLFOX did not fulfill the inclusion criteria. Institutional review board approval (Protocol PA11-0607) was obtained before data retrieval and analysis.
Preoperative CLM Assessment
Preoperative assessment included a medical history, physical examination, laboratory evaluation, and imaging studies. Helical computed tomography of chest, abdomen, and pelvis with liver protocol was used to define the extent and location of CLM. Fluorodeoxyglucose positron emission tomography was used in selected patients to rule out extensive extrahepatic disease and confirm the metastatic nature of atypical lesions. 11 Treatment plans were based on the location and extent of CLM, the presence of extrahepatic disease, and radiographic response to preoperative chemotherapy. The decision to administer preoperative chemotherapy was made by the treating physicians. Hepatectomy was considered in patients in whom computed tomographic volumetry data indicated that all CLM could be safely resected with preservation of a sufficient future liver remnant. In patients with an anticipated insufficient future liver remnant, preoperative portal vein embolization was used to induce hypertrophy.
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Surgical Procedure
During laparotomy, the peritoneal cavity was inspected to identify previously unrecognized extrahepatic disease. Intraoperative sonography of the liver was performed to confirm and to better define the location of CLM and their relation to portal pedicles and hepatic veins. Parenchymal transection was performed under total or selective hepatic inflow vascular exclusion using the Cavitron ultrasonic surgical aspirator (CUSA, Valleylab, Boulder, CO), and hemostasis was achieved using saline-linked cautery (dissecting sealer DS 3.0, Tissuelink Medical, Inc, Dover, NH).
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Postoperative Evaluation
Postoperative mortality was defined as any death within 90 days after liver resection, and postoperative morbidity was defined as any complication within the same time period. Postoperative complications were graded according to a standard classification.
14 Major complications were classified as complications requiring surgical, endoscopic, or radiologic intervention (grade III); life-threatening complications requiring intensive care management (grade IV); and death (grade V). Postoperative liver insufficiency was defined as a postoperative peak serum bilirubin level higher than 7 mg/dL. 15 All specimens were subjected to histologic evaluation to confirm the diagnosis of metastatic CRC, the degree of pathologic response of CLM to preoperative chemotherapy, 16 and the width of the tumor-free surgical margin.
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Somatic Gene Mutation Profiling
To assess the tumor biologic characteristics in patients who received adjuvant FOLFOX, 5-FU, or no chemotherapy for the primary CRC, mass-spectroscopy genotyping for somatic gene mutations was performed. DNA extracted from formalin-fixed paraffinembedded resected CLM was analyzed with Sequenom MassArray technology (Sequenom, Inc, San Diego, CA) using the protocol developed in one of our institutional core facilities. 18 A total of 159 point mutations in 33 genes commonly involved in solid tumors including KRAS, BRAF, NRAS, PIK3CA, FBWX7, and CTNNB1 were tested. Sequenom's MassARRAY system utilizes polymerase chain reaction amplification and single-base primer extension for mutation detection. [19] [20] [21] The analytical sensitivity of the assay [limit of detection (LOD) 5%-10% of mutant DNA in total DNA] is higher than conventional Sanger sequencing (LOD: 10%-20%) and similar to pyrosequencing (LOD: 5%-10%). 22, 23 The advantages offered by the MassARRAY system include high-throughput screening for many hot-spot mutations in parallel, use of minimal DNA (10-50 ng) isolated from formalin-fixed paraffin-embedded tissues, ability to detect coexisting multiple mutations, and cost and time effectiveness.
Statistical Analysis
Quantitative and qualitative variables were expressed as medians (range) and frequencies. Comparisons between groups were analyzed with the chi-square or Fisher exact tests for proportions and the Mann-Whitney U test or Kruskal-Wallis H test for continuous variables, as appropriate. Patients were stratified by type of adjuvant chemotherapy for the CRC and the clinicopathologic characteristics of patients who received adjuvant FOLFOX were compared with those of patients who received 5-FU or no adjuvant chemotherapy. Somatic gene mutation rates were also compared between the 3 patient groups. OS and DFS rates were calculated from the date of liver resection to the date of last follow-up or recurrence, respectively, using the Kaplan-Meier method and were compared using log-rank tests.
To identify factors associated with OS and DFS in the entire study cohort (N = 341), we evaluated the following clinicopathologic variables in a univariate analysis: sex (male vs female), age (> 65 vs ≤ 65 years), primary tumor location (rectum vs colon), regional lymph nodes status of the primary tumor (positive vs negative), number of CLM (multiple vs solitary), adjuvant chemotherapy for CRC (FOLFOX vs 5-FU vs no chemotherapy), diameter of the largest CLM (>3 vs ≤3 cm), preoperative carcinoembryonic antigen (CEA) level (>5 ng/mL vs ≤5 ng/mL), preoperative chemotherapy for CLM (administered vs not), portal vein embolization (performed vs not), blood transfusion required (yes vs no), liver resection margins status on microscopic analysis (R1 vs R0), pathologic response to preoperative chemotherapy (major vs minor), postoperative chemotherapy for CLM (administered vs not), and postoperative complications (yes vs no).
All variables associated with OS or DFS with P < 0.05 in the univariate proportional hazards models were entered into a Cox multivariate regression model with backward elimination. P < 0.05 were considered statistically significant. Statistical analyses were performed using the software IBM SPSS Statistics, version 19 (IBM, Armonk, NY).
RESULTS
Patients and Treatment
Among 1250 consecutive patients with CLM treated at MD Anderson during the study period, 98 patients had been treated with RFA only and were excluded from the study. Patients with synchronous CLM (N = 587) (disease-free interval < 12 months) were also excluded. Concomitant hepatectomy and RFA had been performed in 77 of the remaining 565 patients with metachronous CLM; these patients were excluded from the analysis. Of the remaining 488 patients treated with curative hepatectomy for metachronous CLM, 147 had undergone adjuvant chemotherapy for the primary tumor with agents other than 5-FU or FOLFOX and were thus not included in the analysis. The final study cohort consisted of 341 patients who underwent curative liver resection for metachronous CLM 
Patient Characteristics by Adjuvant Chemotherapy Type for CRC
Patients' characteristics, listed by adjuvant chemotherapy type for CRC, are summarized in Table 1 . Patients who received no adjuvant chemotherapy for CRC have been treated in our center from 1993 to the end of the study period (2010). Patients who received adjuvant 5-FU have been treated in the same time period (1993) (1994) (1995) (1996) (1997) (1998) (1999) (2000) (2001) (2002) (2003) (2004) (2005) (2006) (2007) (2008) (2009) (2010) . FOLFOX has been used for the adjuvant therapy of CRC since 2005. Patients' median age in the FOLFOX group was significantly lower than that in the 5-FU and no chemotherapy groups (P = 0.035). The number of node-positive primary tumors was similar between FOLFOX and 5-FU but lower in the no-chemotherapy group (P < 0.0001). The median metastasis size was smaller in the adjuvant FOL-FOX group (2.5 cm) than in the 5-FU (3.0 cm) and no-chemotherapy (3.5 cm) groups (P = 0.008). Postoperative complications were more common in the FOLFOX group (P = 0.047), but there was no difference in the major complication rates among the 3 groups (P = 0.204). The remaining patient characteristics in the 3 groups were similar, including prehepatectomy chemotherapy utilization (P = 0.110), CLM number (P = 0.579), and preoperative CEA serum level (P = 0.239).
Postoperative Mortality and Morbidity
The postoperative 90-day mortality rate was 2% (6 patients died). Three patients died as a result of postoperative liver insufficiency after an extended hepatectomy following prolonged preoperative chemotherapy. Two deaths were related to pulmonary infection, and 1 patient died of thromboembolic complications (pulmonary embolism). The postoperative 90-day morbidity rate was 27% (93 of 341 patients). Thirteen percent of patients experienced a major complication that necessitated operative, endoscopic, or radiologic intervention.
Long-Term Survival
At a median follow-up duration of 53 months (1-196 months), the 3-and 5-year DFS rates of the entire cohort were 36% and 33%, respectively. The 3-and 5-year OS rates were 72% and 55%, respectively. The DFS rates after resection of CLM were significantly lower in patients treated with adjuvant FOLFOX than in patients treated with 5-FU or no chemotherapy after resection of the primary CRC FIGURE 1. Study inclusion criteria.
(DFS at 3 years: 14% vs 38% vs 45%, respectively, P < 0.0001) (Fig. 2) . Likewise, OS rates were lower in FOLFOX patients than in 5-FU and no chemotherapy patients (OS at 3-years: 58% vs 70% vs 84%, respectively, P = 0.002) (Fig. 3) .
Predictors of Outcome
The results of univariate and multivariate analyses of factors associated with DFS are summarized in Table 2 . On univariate analysis, positive lymph node metastases for the primary tumor (P = 0.023), adjuvant FOLFOX therapy for the primary CRC (P < 0.0001), preoperative chemotherapy for CLM (P = 0.028), and positive surgical margins at CLM resection (P = 0.012) were associated with poor DFS. On multivariate analysis, only the adjuvant FOLFOX therapy for the primary CRC [hazard ratio (HR) = 1.52, 95% confidence interval (CI): 1.23-1.89, P < 0.0001] was independently associated with worse DFS.
The results of the analysis of OS predictors are shown in Table 3 . On univariate analysis, positive lymph node metastases for the primary tumor (P = 0.022), multiple CLM (P = 0.009), adjuvant FOLFOX therapy for the primary CRC (P = 0.002), largest CLM larger than 3 cm (P = 0.002), and positive surgical margins at the CLM resection (P = 0.003) were predictive of poor OS. On multivariate analysis, multiple CLM (HR = 1.52, 95% CI: 1.07-2.17, P = 0.021), adjuvant FOLFOX therapy for the primary CRC (HR = 1.86, 95% CI: 1.36-2.53, P < 0.0001), largest CLM larger than 3 cm (HR = 1.89, 95% CI: 1.31-2.73, P = 0.001), and positive surgical margins at CLM resection (HR = 1.82, 95% CI: 1.13-2.93, P = 0.014) remained significant predictors of OS.
Somatic Gene Mutation Profiling
Among 341 patients in this series, a total of 210 patients operated in the most recent years (FOLFOX = 70, 5-FU = 70, and no chemotherapy = 70) were selected for specimen analysis. Paraffin blocks and sufficient tissue for somatic gene mutation analysis using Sequenom MassArray technology were available in 129 patients (FOLFOX = 47, 5-FU = 41, no chemotherapy = 41). The tumor biologic characteristics of patients treated with adjuvant FOLFOX, 5-FU, or no chemotherapy for the primary CRC were assessed according to the proportions of somatic gene mutations found in each group. One or more mutations were found in 57% of patients (27/47) after FOLFOX, 29% of patients (12/41) after 5-FU, and 32% of patients (13/41) after no chemotherapy (P = 0.011). The mutations included the genes KRAS, BRAF, NRAS, CTNNB1, FBWX7, and PIK3CA. The differences in mutation rates among the groups were related to the proportions of KRAS mutations in each group (P = 0.008). Other mutations were similarly distributed among the 3 groups (Table 4) .
DISCUSSION
Patients with primary CRC and lymph node metastases and those at high risk for metachronous CLM (stage II/III) have been treated with adjuvant chemotherapy, including oxaliplatin in recent years. 3, 7, 8 Nevertheless, some of these patients will develop CLM, which can be successfully treated if they can be completely resected with histologically negative margins. 24, 25 In this study, we analyzed DFS and OS rates after resection of metachronous CLM according to adjuvant chemotherapy type for the primary tumor. After controlling for primary and metastatic disease stage, the primary risk factor associated with poor outcome was treatment with adjuvant FOLFOX after resection of CRC. These findings suggest that the type of adjuvant therapy given after colon resection impacts the tumor biology of the subsequent metastases. To validate this hypothesis, we analyzed somatic gene mutations in CLM. We found a higher rate of mutations in FOLFOX-treated patients, with KRAS mutational status being entirely responsible for this difference. Prior to the oxaliplatin-era, published series reporting on patients who developed metachronous CLM indicated 46% to 62% 3-year DFS and 64% to 75% 3-year OS rates. 9, 26, 27 Our retrospective analysis of prospectively collected CLM patient data demonstrated that the natural history of the subset of metachronous CLM from stage III CRC may have changed after the introduction of oxaliplatinbased chemotherapy. Patients with metachronous CLM treated with 5-FU experienced longer survivals (3-year DFS 38% and OS 70%) than those treated with FOLFOX (3-year DFS 18% and OS 58%). Clinical trials indicate that the use of FOLFOX after primary resection prevents or delays CLM in a larger number of patients than does 5-FU alone, 7, 8 but it may at the same time contribute to the selection of patients with a more aggressive form of metastatic disease-that is, resistant to oxaliplatin and responsible for a poorer OS and DFS after resection of metachronous CLM. Two prospective randomized studies on adjuvant chemotherapy in stage II and III colon cancer patients have demonstrated that patients who recur after adjuvant FOLFOX have shorter OS than patients who recur after randomization to adjuvant 5-FU. 8, 28 In the MOSAIC trial, the median time from relapse to death was 21 months for the FOLFOX group and 24 months for the 5-FU group. 8 This has been previously attributed to the lower efficacy of oxaliplatin regimens upon retreatment of previously FOLFOX-treated patients. According to this hypothesis, these patients have fewer effective chemotherapy regimens and a resulting lower OS. However, our data supports the alternate suggestion that FOLFOX-resistant colon cancer has a different biology than 5-FU-resistant tumors. Preclinical studies suggest that oxaliplatin resistant cell lines develop epithelialto-mesenchymal transition, characterized by a migratory and proinvasive phenotype. 29, 30 As DFS after hepatectomy is dictated by unrecognized microscopic disease outside of the visible metastases, such migratory behavior may contribute to the higher recurrence rates after FOLFOX.
KRAS mutation in primary tumors represents a modest prognostic marker for metastatic CRC patients in some, but not all, clinical series. However, it is clearly associated with resistance to epidermal growth factor receptor inhibitors. [31] [32] [33] [34] KRAS mutation in CLM has also been shown to be associated with lower survival and accelerated disease progression in patients with resected CLM in an era predating FOLFOX chemotherapy. 35 The same study reported a low rate of KRAS mutations (16%), similar to our study, after resection of metachronous CLM. KRAS mutation analysis was additionally used in 2 previous studies to assess the minimum surgical margins in resected CLM. 36, 37 KRAS mutation has recently been associated with higher rates of lung metastases, a common location of recurrence for patients with resected CLM. 32 The current study is the first to characterize KRAS mutation in patients undergoing curative liver resection for metachronous CLM in the era of adjuvant FOLFOX chemotherapy for CRC; the higher rate of KRAS mutation in patients treated with FOLFOX underscores the association between modern chemotherapy and the long-term selection of worse tumor biology. This study is limited by its retrospective nature. The selection of adjuvant chemotherapy regimens in routine patient care is based on many clinical and pathologic factors not fully captured by multivariate analysis; however, the degree of magnitude of the observed effect and the inclusion of multiple prognostic variables argues against this. A prospective study to confirm our findings may not be feasible because chemotherapy with FOLFOX for lymph-node positive CRC is currently the standard of care on the basis of randomized trials. 3, 7, 8 Efforts to replicate this finding from completed randomized adjuvant studies are ongoing. Our study is also limited by the fact that somatic gene mutation profiling using Sequenom MassArray technology could only be performed in a subset of 129 patients. However, this high-throughput technology enabled the testing of 159 different mutations on 33 different genes, allowing evaluation of genes and pathway interactions that could not be evaluated with a single gene study. Another possible limitation of this study is the absence of KRAS status evaluation of the primary tumor. Thus, it was not possible to determine whether a discordance in mutation rates existed between patients who did and did not receive oxaliplatin after resection of the primary. However, numerous studies of KRAS mutational status in primary and metastatic disease sites have shown high concordance rates, ranging from 84% to 100% [38] [39] [40] [41] [42] [43] [44] , whereas only one study, in 21 patients, reported a low concordance rate of 52%. In conclusion, this study suggests that oxaliplatin-based adjuvant therapy may provide a selection pressure favoring a chemotherapy-resistant subset enriched for KRAS mutations while on balance preventing liver recurrences in patients with KRAS wildtype tumors. This change may be responsible for the early recurrence and lower OS observed after resection of metachronous CLM. The selection of patients with chemotherapy-resistant CLM and predestined worse prognosis represents a new challenge for hepatobiliary surgeons in an era that is characterized by multimodal therapy of CLM and the increasing use of perioperative chemotherapy with molecular profiling.
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DISCUSSANT
DR. ANTON BILCHIK (Santa Monica, CA): Dr. Vauthey and his colleagues at MDACC have been instrumental in helping transform metastatic colon cancer into a chronic illness. Using innovative surgical approaches and integrating them with effective systemic chemotherapeutic and biologic agents they have redefined the criteria for resectability in colorectal hepatic metastases. As a result, conventional criteria such as tumor size and number are no longer used to select patients for resection but rather response to chemotherapy and in particular oxaliplatin. Prospective randomized trials have demonstrated that oxaliplatin is superior to 5-FU for the adjuvant treatment of colon cancer and the only randomized trial in liver resection performed by the EORTC demonstrated a survival benefit when given perioperatively compared with hepatic resection alone.
This study challenges conventional dogma and is potentially paradigm changing in suggesting that prior treatment with oxaliplatin may have an adverse effect on the survival of patients undergoing liver resection and the mechanism may be related to an overexpression of KRAS and potentially other molecular markers. It also is consistent with the future of cancer care-individualized treatment, targeted therapy using molecular markers and a reduction in toxicity.
Without knowing the denominator of patients treated and cured with adjuvant oxaliplatin, have you simply selected a subset of patients with worse biology?
Second, I realize you have not analyzed KRAS in the primary tumor but can you speculate whether KRAS may have transformed from wild type to mutant during the metastatic cascade making it more resistant to therapy? Alternatively do you think these KRAS mutations are selected for, rather than induced by oxaliplatin? The study excluded patients undergoing other types of chemo, but what about patients receiving targeted therapies?
Third, your group has recently published that the most important prognostic marker after resection is response to neoadjuvant chemotherapy. Can you explain why only 50-60% patients received neoadjuvant therapy for metastatic disease and was there a difference in KRAS expression based on response to chemotherapy? What neoadjuvant/postop regimens were used and were there any general criteria for determining whether neoadjuvant/postop therapy was indicated?
Fourth, are you suggesting that we reconsider the routine use of oxaliplatin in the adjuvant setting and how do you propose selecting chemotherapy after hepatectomy?
DR. JEAN-NICOLAS VAUTHEY (Houston, TX): In this study, we observed a marked difference in biology and survival in the well-defined metachronous population, which traditionally had good prognosis. While chemotherapy has evolved, we acknowledge the potential biases inherent to this retrospective analysis. We are awaiting further data on mutation rates in patients treated with FOL-FOX to validate our findings.
When we controlled for clinical pathologic factors of outcome, the only factor associated with survival was FOLFOX. Furthermore, in support of our findings, we note that the two randomized controlled studies comparing FOLFOX and 5-FU indicated a lower survival at recurrence in patients treated for six months with oxaliplatin compared to 5-FU. These two studies provide the full denominator of patients treated with adjuvant chemotherapy.
Regarding your second question, did oxaliplatin induce mutations or cause a selection pressure? The mechanism of this finding is unclear and we await validation of this finding in separate cohorts. The current data on mechanism of resistance to oxaliplatin does not support the induction of mutation. Possible explanations include selection pressure with lower response to oxaliplatin in KRAS mutated primary tumors and/or a predilection for FOLFOX-resistant KRAS mutated tumors to present as liver-limited disease. We know that wild type tumors have heterogenous cell populations and mutations present in a small portion of the tumor may not be detected in up to 20% of patients with usual methodologies. Although not previously described, FOLFOX may provide a selection pressure that increases the relative fitness of the KRAS mutant population upon relapse.
Additionally, prior data has demonstrated that KRAS mutation is associated with higher rates of lung metastases, predominantly in synchronous patients or patients not previously treated with adjuvant FOLFOX. As populations with high rates of lung metastases are less likely to be candidates for liver resection, this may explain the low rate of KRAS mutation seen in our untreated or 5-FU treated liver resection patients, as previously described in a prior hepatectomy series (Nash GM. Ann Surg Oncol. 2010;17:572.578). However, adjuvant FOLFOX may alter this dynamic and result in rates of KRAS mutation closer to that seen in unresectable metastastic CRC populations.
Targeted therapy, mostly anti VEGF, has been used in recent years for colorectal metastases prior to resection. This treatment is unlikely to have affected the findings because only half of patients received preoperative treatment prior to liver resection. Only a quarter of patients received biologic agents. In addition, bevacizumab does not target the cancer cell, but VEGF with direct effect on endothelial cells.
The third question regards the effect of preoperative chemotherapy before liver resection on the results and our indication for preoperative chemotherapy in these patients. At our institution, patients who have received chemotherapy within one year do not receive chemotherapy for their colorectal liver metastases prior to resection because of cross resistance between chemotherapy. In the current study, the median onset of metachronous colorectal metastases was about 20 months for all three groups, which explained why chemotherapy was used in half of the patients in these groups. The three groups similarly received preoperative chemotherapy. It is therefore unlikely that this preoperative chemotherapy may have affected the results. As for the results of the subset of patients with or without chemotherapy before liver resection, these subsets are too small for meaningful analysis.
In answer to your fourth question, we would not advocate any change in therapy based on the data presented. We would point out that there is a need for further analysis of mutations in subsets of patients with liver metastases as shown in the current study. This is only the second study to report on survival and KRAS mutations after resection of colorectal liver metastases. This type of analysis should help in understanding differences in outcomes while framing the premises of more personalized care in patients with colorectal liver metastases. Future prospective studies should also account for these mutational changes and increasing resistance to therapy.
DR. MURRAY F. BRENNAN (New York, NY): It is very important that we remind our colleagues that when you have randomized trials that show a difference between 75 and 79%, that it is highly statistically significant as they have large sample numbers. Remember, 75% of people were never going to recur. We completely ignore that group that cannot be benefited.
Second, you should not be surprised that you fail the most effective therapy that you will do worse. What is so surprising about that? The real question is, can you predict those people who will fail? Presumptively, you have the primary tumors to be examined. I believe Dr. Bilchik alluded to that.
My most important point is, we need to remind our colleagues that when we change from 75 to 77%, 75% of the people were never going to benefit. When that becomes the standard of therapy, you can only punish that 75%.
DR. JEAN-NICOLAS VAUTHEY: I would agree and we see this increasingly with extensive chemotherapy for colorectal Copyright © 2012 Lippincott Williams & Wilkins. Unauthorized reproduction of this article is prohibited. liver metastases and late referrals for surgical resection. A minimal change in survival overall may be a big change for us, especially surgeons, as we are at the end of the assembly line for these patients, and we do salvage surgery now for these patients. On balance we also recognize that chemotherapy has led to lower recurrences and improved survivals in the overall population of patients diagnosed with colorectal cancer. This is part of the big picture of improved overall survival of colorectal cancer observed nationwide.
Regarding the primary, we acknowledge the lack of availability of primary for analysis as a limitation of our study. Current efforts are ongoing to validate our findings using follow-up data of previous randomized controlled trials.
DR. HENRI BISMUTH (Villejuif, France): You studied three groups of patients, two with chemotherapy and one without chemotherapy. You mention in one slide that there were fewer lymph node positive in the group without chemotherapy. We may think that this group is less exposed to the occurrence of colorectal liver metastases. Do you think that the better survival rate that you observed could be more related to the absence of lymph node positive, than with the chemotherapy?
As a consequence, adjuvant chemotherapy of the primary cancer could have no influence in the outcome of the resection of colorectal metastases. I speak about the adjuvant chemotherapy for the primary cancer.
DR. JEAN-NICOLAS VAUTHEY: Thank you for pointing to the difference in lymph node positivity and the trend in more positive lymph nodes in the FOLFOX group compared to the 5-FU group. However, lymph node status of the primary tumor was not an independent predictor of survival in multivariate analysis in this study. Likewise, there was no difference in the rate of KRAS mutations between N0 and N1 tumor (29% and 31%, respectively, P=0.837). This data is consistent with our understanding that KRAS is an early molecular event in colorectal cancer carcinogenesis and suggests that the status of the lymph node involvement does not explain the findings presented.
